0001144204-16-112000.txt : 20160707 0001144204-16-112000.hdr.sgml : 20160707 20160707161645 ACCESSION NUMBER: 0001144204-16-112000 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160707 DATE AS OF CHANGE: 20160707 EFFECTIVENESS DATE: 20160707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EYEGATE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-266554 FILM NUMBER: 161756760 BUSINESS ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 781-788-9043 MAIL ADDRESS: STREET 1: 271 WAVERLEY OAKS ROAD STREET 2: SUITE 108 CITY: WALTHAM STATE: MA ZIP: 02452 D 1 primary_doc.xml X0707 D LIVE 0001372514 EYEGATE PHARMACEUTICALS INC 271 WAVERLEY OAKS ROAD SUITE 108 WALTHAM MA MASSACHUSETTS 02452 781-788-8869 DELAWARE None None Corporation true Stephen From 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Director President and CEO Ryan Brenneman 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Executive Officer Chief Financial Officer Paul Chaney 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Morton Goldberg 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Praveen Tyle 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Thomas Balland 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Thomas Hancock 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Bernard Malfroy-Camine 271 Waverley Oaks Road Suite 108 Waltham MA MASSACHUSETTS 02452 Director Pharmaceuticals Decline to Disclose 06b false 2016-06-30 false true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVE. 4TH FLOOR NEW YORK NY NEW YORK 10022 NJ NEW JERSEY false 3768750 3768750 0 Excludes proceeds totaling up to $2,931,250 from the exercise of the warrants. false 2 263813 0 Excludes 33,500 placement agent warrants. 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3. false EYEGATE PHARMACEUTICALS INC /s/ Stephen From Stephen From President and CEO 2016-07-07